MTHFR A1298C polymorphism is associated with cardiovascular risk in end stage renal disease in North Indians

Foley RN, Parfrey PS, Samak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(5 Suppl 3):S112

Bachmann J, Tepel M, Raidt H, Riezler R, Gracte U, Langer K, Zidek W (1995) Hyperhomocstenimia & the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6:121–125

Bostom AG, Shemim D, Verhoef P, Nadeau MR, Jacqueus PF, Selhub J, Dworkin L, Rosenberg IH (1997) Elevated fasting total plasma homocysteine levels & cardiovascular diseases outcomes in maintaineance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 17:2554–2558

Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobson DW, Robinson K, Dennis VW. (1998) Prospective study of hyperhomocysteinimia as an adverse cardiovascular risk factor in end stage renal disease. Circulation 97:138–141

Pastore A, Angelis SD, Casciani S, Ruggia R, Giovamberardino GD, Noce A, Splendiani G ,Cortese C, Federici G, Dessı M (2006) Effects of folic acid before and after vitamin B12 on plasma homocysteine concentrations in hemodialysis patients with known MTHFR genotypes. Clin Chem 52:145–148

Welch GN, Loscalzo J (1998) Homocysteine and atherothrombosis. N Engl J Med 338:1042–1050

Sehlub J (1999) Homocysteine metabolism. Ann Rev Nutr 19:217–246

Frosst P Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuve LP, Rozen R (1995) A candidate genetic risk factor for vascular disease: a common mutation in, methylenetetrahydrofolate reductase. Nat Genet 10:111–113

Weinberg I, Tran P, Christensen B, Sibani S, Rozen R (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Molec Genet Metab 64:1044–1051

Rady PL, Szucs S, Grady J, Hudnall SD, Kellner LH, Nitowsky H, Tyring SK, Matalon RK (2002) Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 107:162–168

Friedman G, Goldschimdt N, Friedlander Y, Ben-Yehuda A, Sehlub J, Babaey S, Mendel M, Kidron M, Bar On H (1999) A common mutation A1298C in human methylenehydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. J Nutr 129:1656–1661

van der Put NMJ, Gabreels F, Stevens EMB, Smeitlink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Biom HJ (1998) A second common mutation in the methylenetetrahydrofolate reductase: an additional risk factor for neural tube defects? Am J Hum Genet 62:1044–1051

Kimura H, Gejyo F, Suzuki S, Miyazaki R (2000) The C677T methylenetetrahydrofolate reducatase gene mutation in hemodialysis patients. J Am Soc Nephrol 11:885–893

Miromoto K, Haneda T, Okamoto K, Ishida H, Kikuchi K (2002) Methylenetetrahydrofolate reductase gene polymorphism. Hyperhomocysteinimia & Cardiovascular diseases in chronic hemodialysis patients. Nephron 90:43–50

Winkelmayer WC, Plassmann GS, Huber A, Fodinger M (2004) Patterns of co-occurrence of three single polymorphisms of the 5, 10–methylenetetrahydrofolate reductase gene in kidney transplant recipients. Eur J Clin Invest 34:613–618

Sidhu PS, Desai SR (1997) A simple and reproducible method for assessing intimal-medial thickness of common carotid artery. Br J Radiol 70:85–89

Lahiri DK, Nurnberger JI Jr (1991) A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acid Res 19:5444

Langman LJ, Wong BYL, Boggis C, Rubin LA, Cole DEC (1998) The prevalence and linkage disequilibrium of three methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms varies in different ethnic groups. Presented at INABIS ‘98—5th Internet World Congress on Biomedical Sciences at McMaster University, Canada, Dec 7–16th. Available at URL: http://www.mcmaster.ca/inabis98/cvdisease/langman0264/index.html

Dennis VW, Robinson K. (1996) Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int 50(Suppl 57):11–17

Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW (1996) Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94:2743–2748

Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH (1992) A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268:877–881

Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ (1994) A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 25:1924–1930

Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH (1996) Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348:1120–1124

Wilcken DEL, Dudman NPB, Tyrell PA, Robertson MA (1988) Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency possible implications for prevention of vascular disease. Metabolism 37:697–701

Arnadottir M, Brattstrom L, Simonsen O, Thysell H, Hultberg B, Andersson A, Nilsson-Ehle P (1993) The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Neph 40:236–240

Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH (1996) High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49:147–52

Dierkes J, Domrose U, Ambrosch A, Bosselmann HP, Neumann KH, Luley C (1999) Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol 51:108–115

Tremblay R, Bonnardeaux A, Geadah D, Busque L, Lebrun M, Ouimet D, Leblanc M (2000) Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hypersoluble vitamins. Kidney Int 58:851–858

Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, Atkins RC, Nicholls K, Fraenkel M, Hutchison BG, Walker R, McNeil JJ (2006) Cardiovascular mortality and mortality in atherosclerosis and folic acid supplementation trial (ASFAST) in chronic renal failure a multicenter randomized, controlled trail. J Am Coll Cardiol 47:1108–1116

Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105

Fodinger M, Buchmayer H, Hienz G, Papagiannopoulos M, Kletzmayr J, Perschi A, Vychytii A, Hori WH, Plassmann GS (2001) Association of two MTHFR polymorphisms with total homocysteine plasma levels in dialysis patients. Am J Kid Dis 38:77–84

Shpichinetsky V, Raz I., Friedlander Y, Goldschmidt N, Wexler ID, Ben-Yehuda A, Friedman G (2000) The association between two common mutation C677T and A1298C in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients. J Nutr 130:2493–2497

Fodinger M, Buchmayer H, Heinz G, Papagiannopoulos M, Kletzmayr J, Rasoul-Rockenschaub S, Horl WH, Sunder-Plassmann G (2000) Effect of MTHFR 1298A > C and MTHFR 677C > T genotypes on total homocysteine, folate, and vitamin B12 plasma concentrations in kidney graft recipients. J Am Soc Nephrol 11:1918–1925

Kumar J, Das SK, Sharma P, Karthikeyan G, Ramakrishnan L, Sengupta S (2005) Homocysteine levels are associated with MTHFR A1298C polymorphism in Indian population. J Hum Genet 50:655–663

Tsai MY, Arnett DK, Eckfeldt JH, William RR, Ellison RC (2000) Plasma homocysteine and its association with carotid intimal medial thickness and prevalent coronary heart disease: NHLBI family heart study. Atherosclerosis 151:519–524

Maroo AO, Doneell CJ (2002) Current practice and future promise for clinical noninvasive measurements of subclinical atherosclerotic disease in the elderly. Am J Geriatr Cardiol 11:108–116

Yokoyama T, Miyauchi K (2002) Carotid artery ultrasound and intravascular ultrasound. Nippon Rinsho 60:922–926

Sun J, Xu Y, Zhu Y, Lu H (2004) Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Res Clin Pract 64:185–190

Ksiazek P, Bednarek-Skublewska A, Buraczynska M (2004) The C677T methylenetetra-hydrofolate reductase gene mutation and nephropathy in type 2 diabetes mellitus. Med Sci Monit 10: BR47–BR51

Moczulski D, Fojcik H, Zukowska-Szczechowska E, Szydlowska I, Grzeszczak W (2003) Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant 18:1535–1540

Noiri E, Taguchi JI, Nakao A, Fujita T (2000) MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Analysis in Japanese male hemodialysis patients. Diabetes Care 23:260

Mtiraoui N, Ezzidi I, Chaieb M, Marmouche H, Aouni Z, Chaieb A, Mahjoub T, Vaxillaire M, Almawi WY (2007) MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabetes Res Clin Pract 75:99–106

Fujita H, Narita T, Meguro H, Ishii T, Hanyu O, Suzuki K, Kamoi K, Ito S (1999) No association between MTHFR gene polymorphism and diabetic nephropathy in Japanese type II diabetic patients with proliferative diabetic retinopathy. J Diabetes Complications 13:284–287

Mukerjee M, Joshi S, Bagadi S, Dalvi M, Rao A, Shetty KR (2002) The low prevalence of the C677T mutation in the methylenetetrahydrofolate reductase gene in Asian Indians. Clin Gent 61:155–159

Lim PS, Hung WR, Wei YH (2001) Polymorphism in methylenetetrahydrofolate reductase gene; its impact on plasma homocysteine levels and carotid artherosclerosis in ESRD patients receiving hemodialysis. Nephron 87:249–256

Haviv YS, Shpichinetsky V, Goldschmidt N, Abou Atta I, Ben-Yehuda A, Friedman G (2002) The common mutations C677T and a1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocstenimia and cardiovascular disease in hemodialysis patients. Nephron 92:120–126

Koupepidou P, Deltas C, Christofides TC, Athanasiou Y, Zouvani I, Pierides A (2005) The MTHFR 677TT and 677CT/1298AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure. Int Angiol 24:287–294